NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
PRVA
Privia Health Group, Inc.
PRVA has the edge over NVO overall, supported by stronger valuation and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRVA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
PRVA's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PRVA in the historical PE scenario, which offers more potential upside but is not a forecast.
PRVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $23.67 | — |
| Current | 88x | $23.67 | — |
| Cheap | 90x | $24.32 | +2.7% |
| Fair | 150x | $40.60 | +72% |
| Expensive | 207x | $55.80 | +136% |
Historical ranges are pointers, not guarantees.
PRVA's PE is in its cheap range at 88x. If earnings grow as analysts expect, today's price would be 54x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PRVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
PRVA has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
PRVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.44 | +61% |
| Q3 2026 | $0.27 | +108% |
| Q2 2026 | $0.22 | +100% |
| Q1 2026 | $0.17 | +42% |
| Q4 2025 | $0.18 | +64% |
| Q3 2025 | $0.13 | +30% |
| Q2 2025 | $0.11 | -8.3% |
| Q1 2025 | $0.12 | -20% |
| Q4 2024 | $0.11 | -42% |
PRVA earned $0.27 per share over the past year, up 108% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PRVA on profitability, with a higher operating margin.
PRVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $657M | +13% |
| Q2 2026 | $632.6M | +21% |
| Q1 2026 | $603.8M | +26% |
| Q4 2025 | $541.2M | +17% |
| Q3 2025 | $580.4M | +33% |
| Q2 2025 | $521.2M | +23% |
| Q1 2025 | $480.1M | +16% |
| Q4 2024 | $460.9M | +4.6% |
PRVA has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | +0.6 points |
| Q2 2026 | 1.9% | +1.2 points |
| Q1 2026 | 1.2% | +0.1 points |
| Q4 2025 | 2.1% | +0.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 0.6% | -0.6 points |
| Q1 2025 | 1.1% | +0.9 points |
| Q4 2024 | 1.1% | +0.8 points |
PRVA's operating margin was 3.1% last quarter, up 0.6 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PRVA on cash flow, with more consistent year-over-year improvement.
PRVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.9M | -44% |
| Q2 2026 | $1.1M | -86% |
| Q1 2026 | -$49.5M | -$25.4M |
| Q4 2025 | $127.5M | +70% |
| Q3 2025 | $52M | +57% |
| Q2 2025 | $8M | -77% |
| Q1 2025 | -$24.1M | +$9.1M |
| Q4 2024 | $74.8M | +17% |
PRVA generated $108M in free cash flow over the past year, down 2.4% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PRVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PRVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +883K shares |
| 1 year | +3.1% | +3.9M shares |
| 3 years | +6.2% | +7.8M shares |
| 5 years | +25% | +26.8M shares |
| Available history | +29% | +29.9M shares |
PRVA has 133M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PRVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -7.0x | Net Cash |
| Q2 2026 | -7.2x | Net Cash |
| Q1 2026 | -8.8x | Net Cash |
| Q4 2025 | -10.9x | Net Cash |
| Q3 2025 | -11.8x | Net Cash |
| Q2 2025 | -14.1x | Net Cash |
| Q1 2025 | -16.3x | Net Cash |
| Q4 2024 | -20.3x | Net Cash |
PRVA has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PRVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 71.7 | Neutral |
PRVA's weekly RSI is 55 (neutral) and its Stochastic is 72 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PRVA on valuation relative to its sector.
PRVA PE vs Healthcare Sector
| Metric | PRVA | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 15 | 36 | 21 pts below |
PRVA is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PRVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.9 | 8% above |
| 20 week MA | $22.7 | 4.4% above |
| 50 week MA | $22.9 | 3.4% above |
| 100 week MA | $22.9 | 3.6% above |
| 200 week MA | $22.6 | 4.9% above |
PRVA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PRVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $36.3 | $26.2 | -28% |
| 2022 | $26.2 | $23.4 | -11% |
| 2023 | $23.4 | $23.0 | -1.6% |
| 2024 | $23.0 | $19.9 | -14% |
| 2025 | $19.9 | $24.1 | +22% |
| 2026 YTD | $24.1 | $23.7 | -1.9% |
PRVA has the edge over NVO on returns for 2026, with the stronger performance.